



Scheduled prepared as of May 16

*\*\*Times noted are CT*

**FRIDAY, June 2 -----**

**1:00 PM CDT**

**Clinical Science Symposium:**

**S406**

**New Partners for EGFR-Mutant Lung Cancer**

- Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer.  
Presenter: **Jacqueline V. Aredo, MD, MS** | UCSF  
Abstract: 8508

**2:45 PM CDT**

**Oral Abstract Session**

**Arie Crown Theater**

**Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary**

- Targets and Triplets in Pancreaticobiliary Tumors  
Discussant: **Andrew H. Ko, MD, FASCO** | UCSF Cancer Center 3:21 PM

SATURDAY, June 3 -----

8:00 AM CDT

Clinical Science Symposium

Hall D1

**The Promise of Neoadjuvant Immunotherapy Across Solid Tumors**

- Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).  
Presenter: **Denise Wolf**. 8:50 am  
Abstract: 102

8:00 AM CDT

Poster Session

Hall A | On Demand

**Genitourinary Cancer—Kidney and Bladder**

- Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.  
Presenter: **Terence W. Friedlander, MD** | UCSF  
Abstract: 4568 | Poster Bd #: 60
- Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.  
Presenter: **Tanya Jindal, BS, BA** | UCSF HDFCCC  
Abstract: 4572. | Poster Bd #: 64
- Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.  
Presenter: **Tanya Jindal, BS, BA** | UCSF HDFCCC  
Abstract: 4573 | Poster Bd #: 65

**Genitourinary Cancer—Prostate, Testicular, and Penile**

- Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging.  
Presenter: **Nonna Shakhnazaryan** | UCSF  
Abstract: 5032 | Poster Bd #: 126
- Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).  
Presenter: **Rahul Raj Aggarwal, MD** | UCSF  
Abstract: 5077. | Poster Bd #: 171
- First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: Randomized phase 2b trial.  
Presenter: **Rahul Raj Aggarwal, MD** | UCSF  
Abstract: TPS5109 | Poster Bd #: 197b

**SATURDAY, June 3 (cont)** -----

- Digital histopathology-based multimodal artificial intelligence scores predict risk of progression in a randomized phase III trial in patients with nonmetastatic castration-resistant prostate cancer.  
Presenter: **Felix Y Feng, MD** | HDFCCC  
Abstract: 5035 | Poster Bd #: 129

**Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology**

- A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with *BRAF*V600-mutated solid tumors.  
Presenter: **Katy K. Tsai, MD** | HDFCCC, UCSF  
Abstract: 3098 | Poster Bd #: 296
- A phase 2 study of the WEE1 inhibitor AZD1775 in *SETD2*-deficient advanced solid tumor malignancies.  
Presenter: **Edward Maldonado, MD** | UCSF  
Abstract: 3104 | Poster Bd #: 302

1:15 PM CDT

Poster Session

Hall A | On Demand

**Melanoma/Skin Cancers**

- Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease.  
Presenter: **Saya Jacob, MD** | UCSF Hem/Onc Fellowship  
Abstract: TPS9595 | Poster Bd #: 356b

**Prevention, Risk Reduction, and Hereditary Cancer**

- Patient-level factors associated with the use of active surveillance: The Talking About Prostate Cancer Cohort.  
Presenter: **Nita Mukand, PharmD, MBA, MPH** | Dept. of Epi/Biostat, UCSF  
Abstract: 10565 | Poster Bd #: 198

3:00 PM CDT

Education Session

S404 | On Demand

**Practicing in a Polarized Society: Ethics and Social Justice in Oncology**

- Ending Systemic Racism in Oncology: The Role and Responsibility of the Clinician  
Speaker: **Ana I. Velazquez Manana, MD, MSc** | UCSF

4:30 PM CDT

Clinical Science Symposium

Hall D1

**No One Left Behind: Enhancing Equity in Oncology**

- Integrating DEI Into the Fellowship Curriculum  
Discussant: **Gerald Hsu, MD, PhD** | San Francisco VA Medical Center

4:30 PM CDT

Poster Discussion Session

S504

**Central Nervous System Tumors**

- Early Endpoints and Late Survival in Central Nervous System Tumors  
Discussant: **Jennie Webster Taylor, MD, MPH** | University of California, San Francisco

SUNDAY, June 4 -----

8:00 AM CDT

Poster Session

Hall A

**Breast Cancer—Metastatic**

- Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2-advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPitello-291 trial.  
Presenter: **Hope S. Rugo, FASCO** | UCSF HDFCCC  
Abstract: 1067 | Poster Bd #: 288
- Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).  
Presenter: **Laura Ann Huppert, MD** | UCSF  
Abstract: 1091 | Poster Bd #: 312
- Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: A single center retrospective cohort study.  
Presenter: **Laura Ann Huppert, MD** | UCSF  
Abstract: 1108 | Poster Bd #: 329

8:00 AM CDT

Poster Discussion Session

Hall A

**Professional Development and Education Advances**

- The cognitive load of inpatient consults involving immune-related adverse events.  
Presenter: **Sam Brondfield, MD, MA** | UCSF  
Abstract: 11033 | Poster Bd #: 486

**Breast Cancer—Local/Regional/Adjuvant**

- Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2.  
Presenter: **Saya Jacob, MD** | UCSF  
Abstract: 611 | Poster Bd #: 441

9:45 AM CDT

Oral Abstract Session

S100a | Live Stream

**Pediatric Oncology 1**

- Microscopes to Molecular: Informing Treatment Approaches in Pediatric Rare Tumors  
Discussant: **Sabine Mueller, MD, PhD** | University of California-San Francisco

SUNDAY, June 4 (cont) -----

9:45 AM CDT

Clinical Science Symposium

E450 | On Demand

**Are Big Data Smart Enough to Answer Questions in Central Nervous System Tumors?**

- Clinical and analytical validation of a targeted gene expression biomarker predicting meningioma outcomes and radiotherapy responses.  
Presenter: **William Cheng Chen, MD** | UCSF Department of Radiation Oncology  
Abstract: 2009
- Clinical Applications of Large Data Sets to Small Neurons  
Discussant: **John Frederick de Groot, MD** | UCSF

11:30 AM CDT

Education Session

S103

**Establishing Equitable Partnerships in Global Cancer Control: Best Practices**

- Partnering to Establish the First Pediatric Oncology Fellowship in Vietnam  
Speaker: **Michelle L. Hermiston, MD, PhD** | UCSF
- Partnering to Establish the First Pediatric Oncology Fellowship in Vietnam  
Speaker: **Dao Thi Thanh An, PhD** | University of Medicine and Pharmacy – UCSF Global Cancer Program Affiliate - leader of Vietnam National Pediatric Hematology-Oncology Fellowship

11:30 AM CDT

Poster Discussion Session

S404 | On Demand

**Professional Development and Education Advances**

- Should I stay, or should I go? Factors associated with intent to leave academic oncology.  
Presenter: **Ana I. Velazquez Manana, MD, MSc** | UCSF  
Abstract: 11004 | Poster Bd #: 457
- Hematology/oncology program director perspectives on recruitment and inclusion of a diverse workforce.  
Presenter: **Ana I. Velazquez Manana, MD, MSc** | UCSF  
Abstract: 11005 | Poster Bd #: 458
- Quality and accessibility of liquid biopsy information: An analysis of online content.  
Presenter: **Henry Kazunaru Litt, MD** | UCSF  
Abstract: 11010 | Poster Bd #: 463

MONDAY, June 5 -----

8:00 AM CT

Education Session

S404

**Structural Sexism and Cancer Care: The Effects on the Patient and Oncologist**

- Defining Structural Sexism in Oncology  
Chair: **Bridget P. Keenan, MD, PhD** | UCSF

8:00 AM CT Education Session

S406

**Global Health | Gastrointestinal Cancer—Colorectal and Anal | Prevention, Risk Reduction, and Hereditary Cancer**

- Making a Case for Colorectal Cancer Screening in Low- and Middle-Income Countries  
Presenter: **Martin Lajous, PhD, MSc, MD** | Instituto Nacional de Salud Publica – UCSF Global Cancer Program Affiliate

8:00 AM CT

Poster Session

Hall A | On Demand

**Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant**

- Longitudinal, prospective cardiovascular and metabolic risk in treatment-naïve patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting.  
Presenter: **Javid J. Moslehi, MD** | UCSF  
Abstract: 7053 | Poster Bd #: 183
- A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).  
Presenter: **Catherine Choy Smith, MD** | Division of Hematology/Oncology, Department of Medicine, HDFCCC, UCSF  
Abstract: TPS7077. | Poster Bd #: 205a

**Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary**

- A phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ).  
Presenter: **Andrew H. Ko, MD, FASCO** | University of California San Francisco  
Abstract: TPS4174 | Poster Bd #: 493b

9:45 AM CDT Science of Oncology Award and Lecture

E451

- Science of Oncology Award Lecture**  
Award Lecturer: **Alan Ashworth, PhD, FRS** | UCSF HDFCCC

MONDAY, June 5 (cont) -----

1:15 PM PDT

Poster Session

Hall A | On Demand

**Head and Neck Cancer**

- Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).  
Presenter: **Hyunseok Kang, MD, MPH** | UCSF  
Abstract: 6040. | Poster Bd #: 32

**Care Delivery and Regulatory Policy**

- Natural language processing identification of documented mental health symptoms associated with risk of mental health disorders in patients with cancer.  
Presenter: **Isabel D Friesner, BA** | UCSF  
Abstract: 1561 | Poster Bd #: 155
- Streamlining regulatory review in a multicenter platform trial: Opportunity to enhance patient centered care and drive innovation and efficiency.  
Presenter: **Paolo Castillo** | UCSF  
Abstract: 1572 | Poster Bd #: 166

**Symptoms and Survivorship**

- Associations of frailty with overall survival (OS) and functional decline among older adults with non-small-cell lung cancer (NSCLC) receiving chemotherapy, immunotherapy, and/or targeted therapy.  
Presenter: **Howard Jinsoo Lee, MD** | UCSF  
Abstract: 12040 | Poster Bd #: 408

4:30 PM PDT

Poster Discussion Session

S504 | On Demand

**Pediatric Oncology**

- Aligning Care Goals in Hard-to-Treat Pediatric Cancers  
Discussant: **Kieuhua Tran Vo, MD, MS** | UCSF

TUESDAY, June 6 -----

8:00 AM CDT

Highlights of the Day Session #3

Hall D1

- Highlights of Melanoma/Skin Cancers  
Discussant: **Katy K. Tsai, MD** | Helen Diller Family Comprehensive Cancer Center, University of California San Francisco



**Twitter:**



**Brand Channels:**

**@UCSFCancer**  
**@UCSFImaging**  
**@NeurosurgUCSF**  
**@ZSFGCare**

**JUNE 3**

*Symposium*

- Jackie Aredo @JackieAredoMD

*Posters*

- Tanya Jindal @Tanjin097
- Felix Feng @felixfengMD
- Katy Tsai @katytsai
- Nita Mukand @NitaMukand

**JUNE 4**

*Symposium*

- William Cheng Chen @WilliamCChen1
- John de Groot @J\_deGrootMD @NeurosurgUCSF

*Posters*

- Ana M. Velazquez @AnaVManana @ZSFGCare
- Hope Rugo @hoperugo
- Laura Huppert @laura\_huppert
- Sam Brondfield @s\_brond

**JUNE 5**

*Education Session*

- Bridget Keenan @bridgetMDPhD

*Award Lecture*

- Alan Ashworth @Ashworth\_SF

*Posters*

- Javid Moslehi @CardioOncology
- Howard Lee @HowardLeeMD

**JUNE 6**

*Highlights of the Day Session*

- Katy Tsai @katytsai